<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2501221640
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MOXIFLOX 400 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MOXIFLOXACIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        49.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DAMMAM PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DAMMAM PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1898]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            DAMMAM PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAMMAM PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Moxiflox contains the active substance moxifloxacin, which belongs to a group of antibiotics called fluoroquinolones. Moxiflox works by killing bacteria that cause infections.</p><p>Moxiflox is used in patients aged 18 years and above for treating the following bacterial infections when caused by bacteria against which moxifloxacin is active. Moxiflox should only be used to treat these infections when usual antibiotics cannot be used or have not worked:</p><p>Infection of the sinuses, sudden worsening of long term inflammation of the airways or infection of the lungs (pneumonia) acquired outside the hospital (except severe cases).</p><p>Mild to moderate infections of the female upper genital tract (pelvic inflammatory disease), including infections of the fallopian tubes and infections of the uterus mucous membrane.</p><p>Moxiflox tablets are not sufficient on their own for treating this kind of infection. Therefore, another antibiotic in addition to Moxiflox tablets should be prescribed by your doctor for the treatment of infections of the female upper genital tract (see section 2. What you need to know before you take Moxiflox, Warnings and precautions, Talk to your doctor before taking Moxiflox).</p><p>If the following bacterial infections have shown improvement during initial treatment with Moxiflox solution</p><p>For infusion, Moxiflox tablets may also be prescribed by your doctor to complete the course of therapy:</p><p>Infection of the lungs (pneumonia) acquired outside the hospital, infections of the skin and soft tissue.</p><p>Moxiflox tablets should not be used to initiate therapy for any type of infections of the skin and soft tissue or in severe infections of the lungs.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Contact your doctor if you are not sure if you belong to a patient group described below.</p><p><strong>Do not take Moxiflox</strong></p><p>- If you are allergic to the active substance moxifloxacin, any other quinolone antibiotics or any of the other ingredients of this medicine (listed in section 6. Further information).</p><p>- If you are pregnant or are breast-feeding.</p><p>- If you are under 18 years of age.</p><p>- If you have previously had problems with your tendons related to treatment with quinolone antibiotics (see section Warnings and Precautions &hellip; and section 4. Possible side effects).</p><p>- If you were born with or have</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; any condition with abnormal heart rhythm (seen on ECG, electrical recording of the heart)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; a salt imbalance in the blood (especially low levels of potassium or magnesium in the blood)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; a very slow heart rhythm (called &lsquo;bradycardia&rsquo;)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; a weak heart (heart failure)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; a history of abnormal heart rhythms or</p><p>- if you are taking other medicines that result in abnormal ECG changes (see section Other medicines and Moxiflox). This is because Moxiflox can cause changes on the ECG, that is a prolongation of the QT-interval, i.e., delayed conduction of electrical signals.</p><p>- If you have a severe liver disease or increased liver enzymes (transaminases) higher than 5 times the upper normal limit.</p><p>&nbsp;</p><p><strong>Take special care with Moxiflox</strong></p><p>&nbsp;</p><p>Talk to your doctor before taking Moxiflox</p><p>- If you have been diagnosed with an enlargement or &ldquo;bulge&rdquo; of a large blood vessel (aortic aneurysm or large vessel peripheral aneurysm).</p><p>- If you have experienced a previous episode of aortic dissection (a tear in the aorta wall).</p><p>- If you have a family history of aortic aneurysm or aortic dissection or other risk factors or predisposing conditions (e.g. connective tissue disorders such as Marfan syndrome, or vascular Ehlers-Danlos syndrome, or vascular disorders such as Takayasu arteritis, giant cell arteritis, Behcet`s disease, high blood pressure, or known atherosclerosis).</p><p>&nbsp;</p><p>If you feel sudden, severe pain in your abdomen, chest, or back, go immediately to an emergency room.</p><p>&nbsp;</p><p>- Moxiflox can change your heart&rsquo;s ECG, especially if you are female, or if you are elderly. If you are currently taking any medicine that decreases your blood potassium levels, consult your doctor before taking Moxiflox (see also sections Do not take and Other medicines and Moxiflox).</p><p>- If you suffer from epilepsy or a condition which makes you likely to have convulsions talk to your doctor before taking Moxiflox.</p><p>- You have ever had mental health problems (as all fluoroquinolones may cause mental health changes such as disturbances in attention, disorientation, agitation, nervousness, memory impairment and delirium).</p><p>-&nbsp; You are diabetic (Hypoglycemia - including hypoglycemic coma- has been reported. If this happens, contact your doctor immediately.)</p><p>- If you suffer from myasthenia gravis (abnormal muscle fatigue leading to weakness and in serious cases paralysis), taking Moxiflox may worsen the symptoms of your disease. If you think you are affected consult your doctor immediately.</p><p>- If you or any member of your family have glucose-6-phosphate dehydrogenase deficiency (a rare hereditary disease), tell your doctor, who will advise whether Moxiflox is suitable for you.</p><p>- If you have a complicated infection of the female upper genital tract (e.g. associated with an abscess of the fallopian tubes and ovaries or of the pelvis), for which your doctor considers an intravenous treatment necessary, treatment with Moxiflox tablets is not appropriate.</p><p>- For the treatment of mild to moderate infections of the female upper genital tract your doctor should prescribe another antibiotic in addition to Moxiflox. If there is no improvement in symptoms after 3 days of treatment, please consult your doctor.</p><p>When taking Moxiflox</p><p>- If you experience palpitations or irregular heart beat during the period of treatment, you should inform your doctor immediately. He/she may wish to perform an ECG to measure your heart rhythm.</p><p>- The risk of heart problems may increase with increase of the dose. Therefore, the recommended dosage should be followed.</p><p>- There is a rare chance that you may experience a severe, sudden allergic reaction (an anaphylactic reaction/shock) even with the first dose. Symptoms include tightness in the chest, feeling dizzy, feeling sick or faint, or dizziness when standing up. If so, stop taking Moxiflox and seek medical advice immediately.</p><p>- Moxiflox may cause a rapid and severe inflammation of the liver which could lead to life-threatening liver failure (including fatal cases, see section 4. Possible side effects). If you suddenly feel unwell and/or are being sick and also have yellowing of the whites of the eyes, dark urine, itching of the skin, a tendency to bleed or liver induced disease of the brain (symptoms of a reduced liver function or a rapid and severe inflammation of the liver) please contact your doctor before taking any more tablets.</p><p>- If you develop a skin reaction or blistering / peeling of the skin and/or mucosal reactions (see section 4. Possible side effects) contact your doctor immediately before you continue treatment.</p><p>- Quinolone antibiotics, including Moxiflox, may cause convulsions. If this happens, stop taking Moxiflox and contact your doctor immediately.</p><p>- You may experience symptoms of neuropathy such as pain, burning, tingling, numbness and/or weakness. If this happens, inform your doctor immediately prior to continuing treatment with Moxiflox.</p><p>- You may experience mental health problems even when taking quinolone antibiotics, including Moxiflox, for the first time. In very rare cases depression or mental health problems have led to suicidal thoughts and self-injurious behaviour such as suicide attempts (see section 4. Possible side effects). If you develop such reactions, stop taking Moxiflox and inform your doctor immediately.</p><p>- You may develop diarrhoea whilst or after taking antibiotics including Moxiflox. If this becomes severe or persistent or you notice that your stool contains blood or mucus you should stop taking Moxiflox immediately and consult your doctor. You should not take medicines that stop or slow down bowel movement.</p><p>- Moxiflox may cause pain and inflammation of your tendons, even within 48 hours of starting treatment and up to several months after discontinuing Moxiflox therapy. The risk of inflammation and rupture of tendons is increased if you are elderly or if you are also taking corticosteroids. At the first sign of any pain or inflammation you should stop taking Moxiflox, rest the affected limb(s) and consult your doctor immediately. Avoid any unnecessary exercise, as this might increase the risk of a tendon rupture (see sections Do not take Moxiflox<em>&hellip; </em>and 4. Possible side effects). .</p><p>- If you are elderly and have kidney problems make sure that you drink plenty whilst taking Moxiflox. If you get dehydrated this may increase the risk of kidney failure.</p><p>- If your eyesight becomes impaired or if your eyes seem to be affected whilst taking Moxiflox, consult an eye specialist immediately (see sections Driving and using machines and 4. Possible side effects).</p><p>- Quinolone antibiotics may make your skin become more sensitive to sunlight or UV light. You should avoid prolonged exposure to sunlight or strong sunlight and should not use a sunbed or any other UV lamp while taking Moxiflox.</p><p>- The efficacy of Moxiflox in the treatment of severe burns, infections of deep tissue and diabetic foot infections with osteomyelitis (infections of the bone marrow) has not been established.</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>&nbsp;</p><p>Do not give this medicine to children and adolescents under the age of 18 because efficacy and safety have not been established for this age group (see section Do not take Moxiflox).</p><p>&nbsp;</p><p><strong>Taking other medicines</strong></p><p>Tell your doctor or pharmacist about any other medicines that you are taking, took recently or might take.</p><p>For Moxiflox, be aware of the following:</p><p>- If you are taking Moxiflox and other medicines that affect your heart there is an increased risk for altering your heart rhythm. Therefore, do not take Moxiflox together with the following medicines:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; medicines that belong to the group of anti-arrhythmics (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; antipsychotics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; tricyclic antidepressants</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; some antimicrobials (e.g. saquinavir, sparfloxacin, intravenous erythromycin, pentamidine, antimalarials particularly halofantrine)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; some antihistamines (e.g. terfenadine, astemizole, mizolastine)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; other medicines (e.g. cisapride, intravenous vincamine, bepridil and diphemanil).</p><p>- You must tell your doctor if you are taking other medicines that can lower your blood potassium levels (e.g. some diuretics, some laxatives and enemas [high doses] or corticosteroids [anti-inflammatory drugs], amphotericin B) or cause a slow heart rate because these can also increase the risk of serious heart rhythm disturbances while taking Moxiflox.</p><p>- Any medicine containing magnesium or aluminium (such as antacids for indigestion), iron, zinc or didanosine or any medicine containing sucralfate (to treat stomach disorders) can reduce the action of Moxiflox tablets. Take your Moxiflox tablet 6 hours before or after taking the other medicine.</p><p>- Taking any medicine containing charcoal at the same time as Moxiflox tablets reduces the action of Moxiflox. It is recommended that these medicines are not used together.</p><p>- If you are currently taking drugs to thin your blood (oral anti-coagulants such as warfarin), it may be necessary for your doctor to monitor your blood clotting time.</p><p>&nbsp;</p><p><strong>Taking Moxiflox with food and drink </strong></p><p>&nbsp;</p><p>Moxiflox can be taken with or without food (including dairy products).</p><p>&nbsp;</p><p><strong>Pregnancy,breast-feeding and fertility </strong></p><p>&nbsp;</p><p>Do not take Moxiflox if you are pregnant or breast-feeding.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Animal studies do not indicate that your fertility will be impaired by taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>&nbsp;</p><p>Moxiflox may make you feel dizzy or light-headed, you may experience a sudden, transient loss of vision, or you may faint for a short period. If you are affected do not drive or operate machinery.</p><p>&nbsp;</p><p>Moxiflox contains lactose</p><p>If you have been told by your doctor that you have an intolerance to some sugars, speak to your doctor before taking Moxiflox.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose for adults is one 400mg film-coated tablet once daily.</p><p>Moxiflox tablets are for oral use. Swallow the tablet whole and with plenty of liquid. You can take Moxiflox with or without food. Try to take the tablet at approximately the same time each day.</p><p>The same dose can be taken by elderly patients, patients with a low bodyweight or in patients with kidney problems.</p><p>The time you will take Moxiflox for depends on your infection. Unless your doctor tells you otherwise, your treatment will be as follows:</p><p>- for sudden worsening (acute exacerbation) of chronic bronchitis 5 - 10 days</p><p>- for infection of the lungs (pneumonia) except for pneumonia which starts during a stay in hospital 10 days</p><p>- for acute infection of the sinuses (acute bacterial sinusitis) 7 days</p><p>- Mild to moderate infections of the female upper genital tract (pelvic inflammatory disease), including infection of the fallopian tubes and infection of the uterus mucous membrane 14 days</p><p>When Moxiflox film-coated tablets are used to complete a course of therapy started with Moxiflox solution for</p><p>infusion, the recommended durations of use are:</p><p>- Infection of the lungs (pneumonia) acquired outside the hospital 7 -14 days</p><p>Most patients with pneumonia were switched to oral treatment with Moxiflox film-coated tablets within 4 days.</p><p>- Infections of the skin and soft tissue 7 -21 days</p><p>Most patients with infections of the skin and soft tissue were switched to oral treatment with Moxiflox film-coated tablets within 6 days.</p><p>It is important that you complete the course of treatment even if you begin to feel better after a few days. If you stop taking Moxiflox too soon your infection may not be completely cured and the infection may return or your condition may get worse. The bacteria causing your infection may become resistant to Moxiflox.</p><p>The recommended dose and duration of treatment should not be exceeded (see section 2. What you need to know before you take Moxiflox, Warnings and precautions).</p><p>&nbsp;</p><p><strong>If you take more Moxiflox than you should </strong></p><p>If you take more than the prescribed one tablet a day, get medical help immediately. Try to take any remaining tablets, the packaging or this leaflet with you to show the doctor or pharmacist what you have taken.</p><p>&nbsp;</p><p><strong>If you forget to take Moxiflox</strong></p><p>&nbsp;</p><p>If you forget to take your tablet you should take it as soon as you remember on the same day. If you do not remember on the same day, take your normal dose (one tablet) on the next day. Do not take a double dose to make up for a forgotten dose.</p><p>If you are unsure about what to do ask your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>If you stop taking Moxiflox</strong></p><p>&nbsp;</p><p>If you stop taking this medicine too soon your infection may not be completely cured. Talk to your doctor if you wish to stop taking your tablets before the end of the course of treatment.</p><p>If you have any further questions about this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects have been observed during treatment with Moxiflox. The frequency of possible side effects listed below is defined using the following convention:</p><p><strong>Common: may affect up to 1 in 10 people </strong></p><p><strong>Uncommon: may affect up to 1 in 100 people </strong></p><p><strong>Rare: may affect up to 1 in 1,000 people </strong></p><p><strong>Very rare: may affect up to 1 in 10,000 people </strong></p><p>Cardiac System (see section 2. What you need to know before you take Moxiflox)</p><p>Common: Change of the heart rhythm (ECG) in patients with low blood potassium level</p><p>Uncommon: Change of the heart rhythm (ECG), palpitations, irregular and fast heartbeat, severe heart rhythm abnormalities, chest pain (angina pectoris)</p><p>Rare: Abnormal fast heart rhythm, fainting</p><p>Very rare: Abnormal heart rhythms, life-threatening irregular heartbeat, stopping of heartbeat</p><p>Common side effects:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections caused by resistant bacteria or fungi, e.g. oral and vaginal infections caused by Candida (thrush)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being sick (vomiting)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach ache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase of a special liver enzyme in the blood (transaminases)</p><p>&nbsp;</p><p>Uncommon side effects:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low red blood cell count (anaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low white blood cells count</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low numbers of special white blood cells (neutrophils)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease or increase of special blood cells necessary for blood clotting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased specialised white blood cells (eosinophils)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased blood clotting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood lipids (fats)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling anxious, restless, or agitated</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingling sensation (pins and needles) and/or numbness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in taste (in very rare cases loss of taste)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling confused and disorientated</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleep problems (e.g. sleeplessness or sleepiness)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shaking</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensation of dizziness (spinning or falling over)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with vision (including double or blurred vision)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Widening of the blood vessels (flushing)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in breathing (including asthmatic conditions)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wind and constipation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach upset (indigestion or heartburn)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the stomach</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase of a special digestive enzyme in the blood (amylase)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with liver function (including increase of a special liver enzyme in the blood (LDH)), increase of bilirubin in the blood, increase of a special liver enzyme in the blood (gamma-glutamyl-transferase and/or alkaline phosphatase)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching, rash, skin hives, dry skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain, muscle pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dehydration</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling unwell (usually weakness or tiredness), aches and pains such as back, chest, pelvic pains and pains in the extremities</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sweating.</p><p>Rare side effects:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe, sudden allergic reaction including very rarely life-threatening shock (e.g. difficulty in breathing, drop of blood pressure, fast pulse), swelling (including potentially life-threatening swelling of the airway)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe diarrhoea containing blood and/or mucus (antibiotic associated colitis including pseudomembranous colitis), which very rarely, may develop into complications that are life-threatening</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice (yellowing of the whites of the eyes or skin), inflammation of the liver</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain and swelling of the tendons (tendonitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood sugar</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood uric acid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling particularly emotional</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression (which in very rare cases may lead to self-harm, such as suicidal ideations/thoughts, or suicide attempts)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hallucination</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with skin sensations</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in smell (including loss of smell)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unusual dreams</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with balance and co-ordination (due to dizziness)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disturbed concentration</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with speech</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Partial or total loss of memory</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Troubles associated with the nervous system such as pain, burning, tingling, numbness and/or weakness in extremities</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringing or noise in the ears, hearing impairment including deafness (usually reversible)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High or low blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in swallowing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle cramps or twitching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney problems (including an increase in special kidney laboratory test results like urea and creatinine), kidney failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling (of the hands, feet, ankles, lips, mouth or throat).</p><p>&nbsp;</p><p>Very rare side effects:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe inflammation of the liver potentially leading to life-threatening liver failure (including fatal cases)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes to the skin and mucous membranes (painful blisters in the mouth/nose or at the penis/vagina), potentially life-threatening (Stevens-Johnson-Syndrome, toxic epidermal necrolysis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rupture of tendons</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood clotting, significant decrease of special white blood cells (agranulocytosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A feeling of self-detachment (not being yourself)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling mentally unwell (potentially leading to self-harm, such as suicidal ideations/thoughts, or suicide attempts)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transient loss of vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin feeling more sensitive</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of joints</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscles feeling stiff</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening of the symptoms of myasthenia gravis (abnormal muscle fatigue leading to weakness and in serious cases paralysis)</p><p>Also, there have been very rare cases of the following side effects reported following treatment with other quinolone antibiotics, which might possibly also occur during treatment with Moxiflox:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood sodium levels</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood calcium levels</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A special type of reduced red blood cell count (haemolyticanaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle reactions with muscle cell damage</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased sensitivity of the skin to sunlight or UV light.</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any side effects not listed in this leaflet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date stated on the blister and carton. The expiry date refers to the last day of the month.</p><p>Store below 30&deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is moxifloxacin. Each film-coated tablet contains 400mg moxifloxacin as hydrochloride.</p><p>- The other ingredients are: Lactose anhydrous NF D.C., Povidon 30, Croscarmellose sodium Type A, Colloidal silicon dioxide, Magnesium stearate, Hydroxypropyl methylcellulose, Titanium dioxide, purified talc, Polyethylene Glycol MW 6000 and Iron oxide red.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                A dull red, bevelled edge, oblong, biconvex, film-coated tablet, engraved with "223" on one side and plain on the other side.
The film-coated tablets are available in packs of   5 and 7 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dammam Pharma</p><p>Saudi Arabia</p><p>Address: 1st industrial city, unit No.1, PO.BOX: 7137, Dammam 32234-4384</p><p>Phone: +966138216444</p><p>Fax: +966138216422</p><p>Email: regulatory-affairs@dammampharma.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2018          
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">موكسيفلوكس يحتوى على مادة موكسيفلوكساسين كمادة فعالة, والتى تنتمى إلى مجموعة من المضادات الحيوية تسمى فلوروكينولونات. موكسيفلوكس يعمل على قتل البكتيريا المسببة للعدوى.</p><p dir="RTL">يستخدم موكسيفلوكس للمرضى البالغين من العمر 18 سنة فما أكثر لعلاج العدوى البكتيرية الآتية والتى تنتج عن الإصابة بالبكتيريا القابلة للقتل عن طريق موكسيفلوكساسين. يجب استخدام موكسيفلوكس لعلاج تلك الحالات من العدوى فقط فى حالة عدم إمكانية استخدام المضادات الحيوية المعتادة أو فى حالة عدم الاستجابة لها:</p><p dir="RTL">العدوى المصيبة للجيوب الأنفية, والتدهور المفاجئ لالتهاب طويل المدى في الشعب الهوائية أو التهاب في الرئتين (التهاب رئوى) المكتسب خارج المستشفى (باستثناء الحالات الشديدة).</p><p dir="RTL">عدوى المسالك التناسلية العلوية من الخفيفة إلى المعتدلة عند الإناث (مرض التهاب الحوض), بما في ذلك التهابات في قناة فالوب والتهابات الغشاء المخاطي للرحم.</p><p dir="RTL">أقراص موكسيفلوكس بمفردها ليست كافية لعلاج هذا النوع من العدوى. لذلك يجب وصف مضادات حيوية أخرى من قبل الطبيب المعالج لعلاج عدوى المسالك التناسلية العلوية لدى الإناث (انظر الفقرة 2. ما يجب مراعاته قبل تناولموكسيفلوكس, التحذيرات والاحتياطات, تحدث إلى طبيبك قبل تناول أقراص موكسيفلوكس).&nbsp;&nbsp;&nbsp;</p><p dir="RTL">فى حالة ظهور تحسن من العدوى البكتيرية الآتية خلال العلاج المبدئى بمحلول موكسيفلوكس عن طريق التسريب بالوريد, يمكن أيضاً للطبيب المعالج وصف أقراص موكسيفلوكس لاستكمال دورة العلاج:</p><p dir="RTL">العدوى التى تصيب الرئتين (الالتهاب الرئوى) المكتسبة خارج المستشفى, وعدوى الجلد والأنسجة الرخوة.</p><p dir="RTL">لا ينبغي استخدام أقراص موكسيفلوكس لبدء العلاج من أي نوع من أنواع عدوى الجلد والأنسجة الرخوة أو في العداوى الشديدة للرئتين.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تواصل مع طبيبك المعالج إذا كنت غير متأكداً من انتمائك إلى مجموعة المرضى الموصوفة أدناه.</p><p dir="RTL">لا تقم بتناول أقراص موكسيفلوكس فى الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانى من فرط التحسس تجاه المادة الفعالة موكسيفلوكساسين, أو أى مضاد حيوى آخر من مجموعة الكينولونات أو أى من المكونات الأخرى لهذا الدواء (والمذكورة فى الفقرة 6. معلومات إضافية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً أو تقومين بإرضاع طفلك طبيعياً.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أقل من 18 سنة من العمر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت مسبقاً من مشاكل بالأوتار والمرتبطة بالعلاج بمضادات حيوية من مجموعة الكينولونات (انظر فقرة التحذيرات والاحتياطات...والفقرة 4. الأعراض الجانبية المحتملة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك منذ ولادتك أى مما يلى:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أى حالة من عدم انتظام إيقاع القلب (والتى تظهر فى تخطيط القلب والتسجيل الكهربائى للقلب).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم توازن الملح فى الدم (خصوصاً انخفاض نسبة البوتاسيوم أو المغنسيوم فى الدم لديك).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تباطؤ شديد فى إيقاع القلب (والتى تسمى بطء القلب).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف بالقلب (فشل القلب).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاريخ من عدم انتظام إيقاع القلب أو إذا كنت تتناول أدوية أخرى قد تسبب تغيرات غير طبيعية فى رسم القلب (انظر فقرة تناول أدوية أخرى مع موكسيفلوكس). وذلك بسبب أن موكسيفلوكس قد يسبب تغيرات فى رسم القلب, والتى تتمثل فى إطالة الفترة QT, بمعنى تأخير توصيل الإشارات الكهربائية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض حاد في الكبد أو ارتفاع فى إنزيمات الكبد (الترانساميناسات) أعلى من 5 أضعاف الحد الأقصى الطبيعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغى توخي الحذر عند تناول<strong> </strong>موكسيفلوكس</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك المعالج قبل تناول أقراص موكسيفلوكس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم تشخيصك بتضخم أو &quot;انتفاخ&quot; في وعاء دموي كبير (تمدد فى وعاء الأبهر (الأورطى) أو تمدد الأوعية الدموية المحيطية الكبيرة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرضت مسبقاً لحالة تمزق في جدار الأورطى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ عائلي من تمدد الأوعية الدموية الأبهري (الأورطى) أو تمزق في جدار الأورطى أو عوامل خطر أخرى أو حالات مهيئة (مثل اضطرابات الأنسجة الضامة مثل متلازمة مارفان أو متلازمة الأيلاروس - دانلوس الوعائية, أو اضطرابات الأوعية الدموية مثل التهاب الشرايين التاكاياسو,أو التهاب شرايين الخلايا الكبرى, مرض بهسيت وارتفاع ضغط الدم, أو تصلب الشرايين).</p><p dir="RTL">إذا شعرت بألم شديد مفاجئ في بطنك أو صدرك أو ظهرك, فتوجه فوراً إلى غرفة الطوارئ.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يسبب موكسيفلوكس تغير فى رسم القلب, خصوصاً فى حالة الإناث, أو فى كبار السن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول حالياً أى دواء يتسبب فى خفض نسبة البوتاسيوم بالدم, استشِر طبيبك المعالج قبل البدء فى تناول أقراص موكسيفلوكس (انظر أيضاً فقرتى لا تقم بتناول موكسيفلوكس فى الحالات الآتية وتناول أدوية أخرى مع موكسيفلوكس).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانى من الصرع أو أى حالة تزيد من تعرضك لتشنجات, تحدث إلى طبيبك المعالج قبل تناول أقراص موكسيفلوكس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك من أي وقت مضى مشاكل في الصحة العقلية&nbsp;(حيث أن كل&nbsp;الفلوروكينولونات&nbsp;قد تسبب تغيرات في الصحة العقلية مثل&nbsp;الاضطرابات في الانتباه ، والتوهان ، والإرتباك ، والعصبية ،&nbsp;وضعف الذاكرة والهذيان)&nbsp;.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مريض بالسكر&nbsp;(تم الإبلاغ عن نقص السكر في الدم - بما في ذلك غيبوبة سكر الدم. إذا حدث هذا ، اتصل بطبيبك على الفور.)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانى من الوهن العضلى الشديد (وهو إرهاق غير طبيعى بالعضلات قد يؤدى إلى ضعف وفى الحالات الشديدة إلى شلل), تناول أقراص موكسيفلوكس قد يسبب تفاقم أعراض هذا المرض لديك. إذا كنت تعتقد فى تأثرك بذلك تواصل مع طبيبك المعالج فوراً.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت أو أى فرد من أفراد عائلتك مصاباً بنقص إنزيم جلوكوز-6-فوسفات النازع للهيدروجين (وهو مرض وراثى نادر), أخبر طبيبك المعالج ليفيدك ما إذا كان موكسيفلوكس مناسباً لحالتك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للإناث: إذا كنتِ مصابة بعدوى معقدة فى المسالك التناسلية العلوية (على سبيل المثال عدوى مصحوبة بخراج فى قنوات فالوب والمبايض أو فى الحوض), فى هذه الحالة يعتبر طبيبك المعالج استخدام العلاج عن طريق الحقن بالوريد ضرورياً, حيث أن العلاج بأقراص موكسيفلوكس يكون غير مناسباً.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فى حالة علاج الالتهابات من الخفيفة إلى المتوسطة فى المسالك التناسلية العلوية للإناث, ينبغى على الطبيب المعالج وصف مضاد حيوى آخر بالإضافة إلى موكسيفلوكس. فى حالة عدم تحسن الأعراض بعد ثلاثة أيام من العلاج, فضلاً استشِر طبيبك المعالج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فى حالة تعرضك لخفقان بالقلب أو عدم انتظام فى ضربات القلب خلال فترة العلاج, يجب عليك إخبار طبيبك المعالج فوراً. فقد يحتاج إلى إجراء رسم قلب كهربائى لقياس إيقاع القلب لديك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خطورة الإصابة بمشاكل القلب قد تزداد مع زيادة الجرعة. لذلك, ينبغى الالتزام بالجرعة الموصوفة لك من قبل الطبيب المعالج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هناك فرصة نادرة لتعرضك لتفاعل تحسسى شديد ومفاجئ (صدمة نتيجة الحساسية) حتى مع الجرعة الأولى. والتى تتضمن أعراضها ضيق في الصدر, والشعور بالدوار, والشعور بالمرض أو الإغماء أو الدوخة عند الوقوف. فى حالة حدوث كذلك, توقف عن تناول موكسيفلوكس واطلب المشورة الطبية على الفور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موكسيفلوكس قد يسبب التهاب شديد وسريع في الكبد مما قد يؤدي إلى فشل الكبد الذى يهدد الحياة (بما في ذلك الحالات القاتلة, انظر القسم 4. الأعراض الجانبية المحتملة). إذا كنت تشعر بشكل مفاجئ بتوعك و / أو إعياء مصحوباً أيضاً باصفرار بياض العينين وظهور البول باللون الداكن وحكة في الجلد, وميل للنزف أو مرض الكبد الناجم عن المخ (أعراض انخفاض وظائف الكبد أو التهاب سريع وحاد بالكبد) يرجى الاتصال بطبيبك المعالج قبل تناول أى أقراص إضافية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فى حالة تعرضك لتفاعل بالجلد أو ظهور تقرحات / تقشير الجلد و / أو تفاعلات مخاطية (انظر القسم 4. الأعراض الجانبية المحتملة) اتصل بطبيبك المعالج على الفور قبل مواصلة العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية من مجموعة الكينولونات, ومن ضمنها موكسيفلوكس, قد تسبب تشنجات. فى حالة تعرضك لذلك, توقف عن تناول موكسيفلوكس واتصل بطبيبك المعالج فوراً.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتعرض لأعراض اعتلال الأعصاب مثل وجود ألم, إحساس بالحرق, وخز, تنميل و/ أو ضعف. فى حالة حدوث ذلك أبلغ طبيبك المعالج فى الحال قبل الاستمرار فى العلاج بأقراص موكسيفلوكس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتعرض إلى مشكلات تتعلق بالصحة النفسية عند تناولك للمضادات الحيوية من مجموعة الكينولونات ومنها موكسيفلوكس حتى ولو لأول مرة. فى حالات نادرة جداً الاكتئاب أو هذه المشكلات النفسية قد تؤدى إلى أفكار انتحارية وإلحاق الضرر بالنفس مثل محاولات الانتحار (انظر القسم 4. الأعراض الجانبية المحتملة). إذا تعرضت لهذه التفاعلات, توقف عن تناول أقراص موكسيفلوكس وأخبر طبيبك المعالج فى الحال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتعرض للإصابة بالإسهال أثناء أو بعد تناولك للمضادات الحيوية ومنها موكسيفلوكس. فى حالة ما أصبحت هذه الحالة شديدة أو مستمرة أو إذا لاحظت وجود دم أو مخاط بالبراز, ينبغى أن تتوقف عن تناول موكسيفلوكس وتخبر طبيبك المعالج فى الحال. يجب عليك عدم تناول أى أدوية تعمل على إيقاف أو تقليل حركة الأمعاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موكسيفلوكس قد يسبب لك ألم والتهاب فى الأوتار, حتى فى خلال 48 ساعة من بدء العلاج إلى حد يصل إلى شهور عديدة بعد التوقف عن تناول أقراص موكسيفلوكس. خطورة الإصابة بالتهاب وتمزق الأوتار تزداد إذا كنت من كبار السن أو إذا كنت أيضاً تتناول الكورتيزونات. عند ظهور أول علامة لوجود ألم أو التهاب ينبغى عليك التوقف عن تناول موكسيفلوكس وإراحة الطرف أو الأطراف المصابة واستشارة طبيبك المعالج فى الحال. تجنب أى مجهود بدنى لا داعى له, حيث أنه قد يزيد من خطورة تمزق الأوتار (انظر فقرة لا تقم بتناول موكسيفلوكس فى الحالات الآتية والفقرة 4. الأعراض الجانبية المحتملة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت من كبار السن ولديك مشاكل فى الكلى تأكد من شربك لكمية كبيرة من السوائل أثناء العلاج بموكسيفلوكس. حيث أنك لو تعرضت للجفاف قد يزيد ذلك من خطورة إصابتك بالفشل الكلوى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فى حالة إصابتك بضعف البصر أو ظهور تأثير على عينيك أثاء تناولك لموكسيفلوكس, استشِر طبيب متخصص فى العيون فى الحال (انظر فقرة القيادة واستخدام الآلات وفقرة 4. الأعراض الجانبية المحتملة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية من مجموعة الكينولونات قد تزيد من حساسية الجلد تجاه ضوء الشمس أو الأشعة فوق البنفسجية. لذلك يجب عليك تجنب التعرض لضوء الشمس لفترة طويلة أو ضوء الشمس القوى وتجنب استخدام أى مصباح للأشعة فوق البنفسجية أثناء تناول موكسيفلوكس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاعلية أقراص موكسيفلوكس في علاج الحروق الشديدة, والتهابات الأنسجة العميقة والتهابات القدم السكري مع التهاب العظم والنقي (التهابات في نخاع العظام) لم يتم التأكد منها.</p><p dir="RTL">الأطفال والمراهقين<br />&nbsp;</p><p dir="RTL">لا يوصف هذا الدواء للأطفال والمراهقين الأقل فى العمر من 18 سنة حيث أن فاعلية وأمان هذا الدواء لم يتم التأكد منها لهذه الفئة العمرية من المرضى (انظر فقرة لا تقم بتناول موكسيفلوكس فى الحالات الآتية).</p><p dir="RTL">تناول أدوية أخرى</p><p dir="RTL">أخبر طبيبك المعالج أو الصيدلى بشأن أى أدوية أخرى تتناولها حالياً أو تناولتها مؤخراً أو قد تتناولها.</p><p dir="RTL">عند تناول موكسيفلوكس, يجب الحرص مما يلى:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند تناولك لأقراص موكسيفلوكس مع أدوية أخرى تؤثر على القلب فذلك يزيد من خطورة الإصابة بعدم انتظام إيقاع القلب لديك. لذلك, يجب عليك عدم تناول أقراص موكسيفلوكس متزامناً مع الأدوية الآتية:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تنتمي إلى مجموعة الأدوية المضادة لعدم انتظام ضربات القلب (مثل كينيدين, هيدروكينيدين, ديزوبيراميد, أميودارون, سوتالول, دوفيتيليد, إيبوتيليد).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الذهان (مثل الفينوثيازين, بيموزيد, سيرتيندول, هالوبيريدول, سولتوبريد).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب ثلاثية الحلقات.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الميكروبات (مثل ساكوينافير, سبارفلوكساسين, إريثروميسين في الوريد, البنتاميدين والأدوية المضادة للملاريا خاصةً هالوفانترين).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الهستامين (مثل تيرفينادين, أستيميزول, ميزولاستين).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى (مثل سيسابريد, فينكامين في الوريد, بيبريديل ودايفيمانيل).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; يجب عليك إخبار طبيبك المعالج إذا كنت تتناول أى أدوية أخرى قد تقلل من مستوى البوتاسيوم فى الدم لديك (مثل بعض مدرات البول, بعض الملينات والحقن الشرجية [بجرعات عالية] أو الكورتيزونات [وهى أدوية مضادة للالتهاب], أمفوتيريسين ب) أو الأدوية التى تبطئ من ضربات القلب حيث أن هذه الأدوية قد تزيد من خطورة الاضطرابات الخطيرة التى تحدث فى إيقاع القلب أثناء تناول أقراص موكسيفلوكس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; أى دواء يحتوى على مغنسيوم أو ألومنيوم (مثل مضادات الحموضة التى تستخدم فى عسر الهضم), الحديد, الزنك, ديدانوزين أو أى دواء يحتوى على سوكرالفيت (لعلاج اضطرابات المعدة) قد يقلل من تأثير أقراص موكسيفلوكس. قم بتناول أقراص موكسيفلوكس قبل أو بعد تناول هذه الأدوية ب 6 ساعات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; تناول أى أدوية تحتوى على الفحم فى نفس وقت تناول أقراص موكسيفلوكس يقلل من تأثير أقراص موكسيفلوكس. لذلك يوصى بعدم استخدام هذه الأدوية بالتزامن مع بعضها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تتناول حالياً أدوية تعمل على ترقيق الدم (أدوية مضادة للتخثر عن طريق الفم مثل الوارفارين), قد يكون من الضرورى قيام طبيبك المعالج برصد وقت تخثر الدم لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول موكسيفلوكس مع الطعام والشراب</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن تناول أقراص موكسيفلوكس مع أو بدون الطعام (بما في ذلك منتجات الألبان).</p><p dir="RTL">&nbsp;</p><p dir="RTL">الحمل و الرضاعة الطبيعية والخصوبة</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقومى بتناول أقراص موكسيفلوكس إذا كنتِ حاملاً أو ترضعين طفلك طبيعياً.</p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين طفلك طبيعياً أو تعتقدين بأنك حامل أو تخططين لإنجاب طفل, يرجى استشارة طبيبك المعالج أو الصيدلى قبل تناول هذا الدواء.</p><p dir="RTL">الدراسات التى أجريت على الحيوانات لا تشير إلى ضعف الخصوبة عند تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيادة واستخدام الآلات</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تشعرك أقراص موكسيفلوكس بالدوار أو الدوخة, وقد تتعرض إلى فقدان مؤقت للرؤية بشكل مفاجئ أو قد تتعرض لإغماء لوقت قصير. فى حالة تأثرك لا تقم بالقيادة أو استخدام الآلات.</p><p dir="RTL">يحتوى موكسيفلوكس على لاكتوز</p><p dir="RTL">إذا أخبرك طبيبك أنك لا تتحمل بعض أنواع السكر. تحدث إلى طبيبك قبل تناول موكسيفلوكس.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول هذا الدواء تماماً كما أخبرك الطبيب المعالج أو الصيدلى. إذا كنت غير متأكداً تحقق من خلال الطبيب المعالج أو الصيدلى.</p><p dir="RTL">الجرعة الموصى بها للبالغين هى قرص واحد 400 ملجم مرة واحدة يومياً.</p><p dir="RTL">يتم تناول أقراص موكسيفلوكس عن طريق الفم. قم بابتلاع القرص كاملاً&nbsp; مع شرب كمية كبيرة من السوائل. يمكنك تناول أقراص موكسيفلوكس مع أو بدون الطعام. حاول أن تتناول القرص فى نفس الوقت تقريباً كل يوم.</p><p dir="RTL">يمكن تناول نفس الجرعة للمرضى كبار السن أو المرضى الذين يعانون من انخفاض وزن الجسم أو المرضى المصابين بمشاكل بالكلى.</p><p dir="RTL">الفترة الزمنية اللازمة لعلاجك بأقراص موكسيفلوكس تعتمد على نوع العدوى عندك. ما لم يخبرك طبيبك المعالج خلاف ذلك, سوف يكون علاجك كالآتى:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فى حالة التدهور المفاجئ (التفاقم الحاد) لالتهاب الشعب الهوائية المزمن من 5 - 10 أيام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فى حالة العدوى التى تصيب الرئتين (الالتهاب الرئوى) فيما عدا الالتهاب الرئوى المكتسب أثناء الإقامة بالمستشفى ستكون مدة العلاج 10 أيام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فى حالة العدوى الحادة التى تصيب الجيوب الأنفية (التهاب بكتيري حاد بالجيوب الأنفية) ستكون مدة العلاج 7 أيام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فى حالة الالتهابات من الخفيفة إلى المتوسطة التى تصيب المسالك التناسلية العلوية عند الإناث (مرض التهاب الحوض), بما في ذلك العدوى التى تصيب قنوات فالوب وعدوى الغشاء المخاطي للرحم ستكون مدة العلاج 14 يوماً.</p><p dir="RTL">فى حالة استخدام موكسيفلوكس أقراص مغلفة&nbsp; بطبقة رقيقة لاستكمال دورة العلاج التى بدأت باستخدام موكسيفلوكس محلول للتسريب بالوريد, تكون مدة العلاج كالآتى:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فى حالة العدوى التى تصيب الرئتين (الالتهاب الرئوى) المكتسب خارج المستشفى تكون مدة العلاج من 7- 14 يوماً. يتم تحويل معظم المرضى المصابين بالتهاب رئوى إلى العلاج عن طريق الفم بأقراص موكسيفلوكس المغلفة بطبقة رقيقة خلال 4 أيام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فى حالة العدوى التى تصيب الجلد والأنسجة الرخوة تكون مدة العلاج من 7- 21 يوماً. يتم تحويل معظم المرضى المصابين بعدوى فى الجلد والأنسجة الرخوة إلى العلاج عن طريق الفم بأقراص موكسيفلوكس المغلفة بطبقة رقيقة خلال 6 أيام.</p><p dir="RTL">من الضرورى عليك استكمال دورة العلاج حتى إذا بدأت تشعر بتحسن بعد أيام قليلة. إذا توقفت عن تناول أقراص موكسيفلوكس قبل الأوان فقد يؤدى ذلك إلى عدم الشفاء التام وربما عودة العدوى إليك مرة أخرى أو ازدياد سوء حالتك. قد تصبح البكتيريا المسببة للعدوى مقاومة لموكسيفلوكس.</p><p dir="RTL">لا يجب تجاوز الجرعة الموصوفة والفترة الزمنية اللازمة للعلاج (انظر الفقرة 2. ما يجب مراعاته قبل تناول أقراص موكسيفلوكس, التحذيرات والاحتياطات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تناولت أقراص موكسيفلوكس أكثر مما ينبغى</p><p dir="RTL">إذا تناولت أكثر من الجرعة الموصوفة وهى قرص واحد يومياً, اطلب المساعدة الطبية فوراً. حاول أن تأخذ معك ما تبقى لديك من أقراص أو خذ معك العبوة أو هذه النشرة لإفادة الطبيب أو الصيدلى بالدواء الذى تناولته.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فى حالة نسيان تناول أقراص موكسيفلوكس</p><p dir="RTL">إذا نسيت تناول الجرعة الموصوفة لك, تناولها حالما تتذكر فى نفس اليوم. إذا لم تتذكر فى نفس اليوم, قم بتناول الجرعة العادية (قرص واحد) فى اليوم التالى. لا تقم بمضاعفة الجرعة لتعويض الجرعة المفقودة. إذا لم تكن متأكداً من كيفية التصرف اسأل الطبيب أو الصيدلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فى حالة التوقف عن تناول أقراص موكسيفلوكس</p><p dir="RTL">إذا توقفت عن تناول أقراص موكسيفلوكس قبل الأوان فقد لا يتم شفاؤك بشكل كامل. تحدث إلى طبيبك المعالج إذا كنت ترغب فى التوقف عن تناول الدواء قبل إتمام دورة العلاج.</p><p dir="RTL">إذا كانت لديك أى أسئلة إضافية بشأن هذا الدواء, اسأل الطبيب أو الصيدلى.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية, هذا الدواء قد يسبب أعراضاً جانبية وإن لم تحدث لكل من يتناول هذا الدواء. الأعراض الجانبية الآتية تمت ملاحظتها أثناء العلاج بواسطة موكسيفلوكس. يتم تعريف معدل تكرار الأعراض الجانبية المحتملة المذكورة أدناه من خلال المصطلحات الآتية:</p><p dir="RTL">شائعة: معدل إصابتها قد يصل إلى 1 من كل 10 مستخدمين لهذا الدواء.</p><p dir="RTL">غير شائعة: معدل إصابتها قد يصل إلى 1 من كل 100 مستخدم لهذا الدواء.</p><p dir="RTL">نادرة: معدل إصابتها قد يصل إلى 1 من كل 1000 مستخدم لهذا الدواء.</p><p dir="RTL">نادرة جداً: معدل إصابتها قد يصل إلى 1 من كل 10,000 مستخدم لهذا الدواء.</p><p dir="RTL">نظام القلب (انظر الفقرة 2. ما يجب مراعاته قبل تناول موكسيفلوكس)</p><p dir="RTL">شائعة: تغير فى إيقاع القلب (والذى يتضح من خلال رسم القلب الكهربائى) عند المرضى المصابين بنقص فى مستوى البوتاسيوم بالدم.</p><p dir="RTL">غير شائعة: تغير فى إيقاع القلب (والذى يتضح من خلال رسم القلب الكهربائى), خفقان, تسارع وعدم انتظام ضربات القلب, اضطرابات حادة فى إيقاع القلب, ألم بالصدر (الذبحة الصدرية)</p><p dir="RTL">نادرة: تسارع غير طبيعى فى إيقاع القلب وإغماء.</p><p dir="RTL">&nbsp;نادرة جداً: اضطرابات فى إيقاع القلب, عدم انتظام فى ضربات القلب مهدد للحياة, توقف نبض القلب.</p><p dir="RTL">أعراض جانبية شائعة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى تسببها بكتيريا مقاومة أو فطريات, مثل عدوى مهبلية أو فموية مسببة عن طريق الكانديدا (مرض القلاع).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء (غثيان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعياء (قئ)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع إنزيمات الكبد فى الدم (الترانساميناسات)</p><p dir="RTL">أعراض جانبية غير شائعة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء (أنيميا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد نوع خاص من خلايا الدم البيضاء (خلايا العدلات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص أو زيادة فى خلايا الدم المتخصصة اللازمة لتخثر الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة عدد نوع خاص من خلايا الدم البيضاء (الحمضات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص فى تخثر الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع دهون الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالقلق وضيق الصدر أو الهياج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بوخز إبر ودبابيس&nbsp; و/ أو تنميل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات فى حاسة التذوق (وفى حالات نادرة جداً فقدان التذوق)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم التركيز والارتباك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالنوم (مثل عدم النوم أو النعاس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوخة (الدوار أو السقوط)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل فى الرؤية (وتشمل ازدواج أو عدم وضوح الرؤية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توسع فى الأوعية الدموية (احمرار)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة فى التنفس (وتشمل حالات حساسية الصدر)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريح و إمساك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب فى المعدة (مثل عسر الهضم أو حرقة المعدة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب فى المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة إنزيم خاص بالهضم فى الدم (أميليز)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل فى وظائف الكبد (وتشمل زيادة نسبة إنزيم متخصص بالكبد فى الدم (LDH)), ارتفاع نسبة البيليروبين فى الدم, زيادة نسبة إنزيم متخصص بالكبد فى الدم (جاما- جلوتاميل- ترانسيفيريز و/ أو فوسفاتيز القلوية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة بالجلد, طفح جلدى, الشرى, جفاف الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل أو العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بعدم الارتياح (يتمثل عادةً فى ضعف أو إرهاق), آلام فى بعض الأماكن مثل الظهر, الصدر, الحوض وآلام فى الأطراف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرق</p><p dir="RTL">أعراض جانبية نادرة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية شديدة ومفاجئة وتشمل حالات نادرة جداً لصدمة الحساسية التى تهدد الحياة (مثل صعوبة فى التنفس, هبوط فى ضغط الدم, سرعة النبض), تورم (بما فيها تورم المسالك الهوائية المهدد للحياة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال شديد يحتوى على دم و/ أو مخاط (حالات التهاب الأمعاء المصاحبة لتناول المضادات الحيوية بما فى ذلك حالة التهاب القولون الغشائي), والتى قد تتطور فى حالات نادرة جداً إلى مضاعفات تهدد الحياة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان (وهى اصفرار بياض العينين أو الجلد), التهاب الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وتورم فى الأوتار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة السكر بالدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة حمض البوليك بالدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الشعور العاطفى بشكل خاص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب (والذى قد يؤدى فى حالات نادرة جداً إلى إلحاق الأذى بالنفس, مثل التفكير بالانتحار أو محاولة الانتحار)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هلوسة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل تتعلق بإحساس الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات فى حاسة الشم (وتشمل فقدان حاسة الشم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحلام غير معتادة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل فى التوازن والتنسيق (نتيجة الدوخة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب فى التركيز</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل فى الكلام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان كلى أو جزئى للذاكرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل تتعلق بالجهاز العصبى مثل ألم, إحساس بالحرق, وخز, تنميل و/ أو ضعف فى الأطراف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين أو ضجيج فى الأذن, خلل فى السمع بما فى ذلك الصمم (وعادةً ما يكون عكسياً)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع أو انخفاض فى ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة فى البلع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب فى الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات أو تشنج فى العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف بالعضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالكلى (وتشمل زيادة فى نتائج اختبارات المعمل الخاصة بالكلى مثل اليوريا والكرياتينين) و الفشل الكلوى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (فى اليدين أو القدمين أو الكاحلين أو الشفتين أو الفم أو الحلق).</p><p dir="RTL">أعراض جانبية نادرة جداً</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب حاد فى الكبد والذى قد يتطور إلى فشل كبدى يهدد الحياة (بما فى ذلك الحالات القاتلة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات فى الجلد والأغشية المخاطية (ظهور تقرحات مؤلمة بالفم / الأنف أو فى القضيب / المهبل), الحالات التى تهدد الحياة (مثل متلازمة ستيفنز- جونسون, انحلال البشرة النخري السام)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمزق الأوتار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة تخثر الدم, نقص ملحوظ فى خلايا الدم البيضاء المتخصصة (ندرة المحببات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بانفصال فى الشخصية (وهى أن تكون غير نفسك)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بخلل فى الصحة النفسية (والذى قد يؤدى إلى إلحاق الأذى بالنفس, مثل الأفكار الانتحارية أو محاولات الانتحار)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان مؤقت للرؤية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حساسية الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بالمفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بتيبس العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور أعراض مرض الوهن العضلى الوبيل (إرهاق غير طبيعى بالعضلات يؤدى إلى ضعف وفى الحالات الخطرة يسبب الشلل)</p><p dir="RTL">أيضاً هناك حالات نادرة جداً من الأعراض الجانبية الآتية قد تم تسجيلها عند استخدام مضادات حيوية أخرى من مجموعة الكينولونات, والتى من المحتمل أن تحدث عند استخدام موكسيفلوكس:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة نسبة الصوديوم بالدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة نسبة الكالسيوم بالدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص فى عدد نوع معين من خلايا الدم الحمراء (فقر الدم الانحلالي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات بالعضلات مع تلف بالخلايا العضلية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حساسية الجلد تجاه ضوء الشمس أو الآشعة فوق البنفسجية</p><p dir="RTL">إذا تعرضت لأى أعراض جانبية, تواصل مع طبيبك المعالج أو الصيدلى. ذلك يشمل أى أعراض جانبية أخرى لم يتم ذكرها فى هذه النشرة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيداً عن نظر ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على الشريط والعبوة. علماً بأن تاريخ الصلاحية يشير إلى آخر يوم فى الشهر المذكور على العبوة.</p><p dir="RTL">يحفظ فى درجة حرارة أقل من 30&deg; م</p><p dir="RTL">لا تقم بالتخلص من أى أدوية عبر النفايات المنزلية أو مياه الصرف الصحى. اسأل الصيدلى عن كيفية التخلص من الأدوية التى لم تعد بحاجة إليها. فهذه التدابير سوف تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هى: موكسيفلوكساسين. حيث يحتوى كل قرص مغلف بطبقة رقيقة على 400 ملجم موكسيفلوكساسين على هيئة هيدروكلورايد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هى: لاكتوز غير مائى إن إف دى سى و بوفيدون 30 و كروسكارميلوز صوديوم نوع أ و سيليكون ثنائى التأكسد غروى و ماغنسيوم ستياريت و هيدروكسى بروبيل ميثيل سيليلوز و تيتانيوم ثنائى التأكسد و تلك منقى و بولى إيثيلين جليكول إم دبليو 6000 و أكسيد حديد أحمر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">أقراص ذات لون أحمر باهت مشطوفة الحافة و مستطيلة و محدبة الوجهين و مغلفة بطبقة رقيقة و محفور على أحد الوجهين &quot;223&quot; و عادية على الوجه الآخر.</p><p dir="RTL" style="text-align:right">تحتوى كل عبوة على 5 أو 7 أقراص.</p><p dir="RTL" style="text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الدمام فارما</p><p dir="RTL">العنوان: المدينة الصناعية الأولى , وحدة رقم 1 , صندوق بريد: 7137 , الدمام 32234 &ndash; 4384</p><p dir="RTL">تليفون: 966138216444+</p><p dir="RTL">فاكس: 966138216422+</p><p>regulatory-affairs@dammampharma.saالبريد الإلكتروني:</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر2018.                                 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Moxiflox 400 mg film-coated tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Each film-coated tablet contains 400 mg moxifloxacin (as hydrochloride). 
For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Film-Coated Tablet.
A dull red, bevelled edge, oblong, biconvex film-coated tablet, engraved with "T223"on one side and plain on the other side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Moxiflox 400 mg film-coated tablets are indicated for the treatment of the following bacterial infections in patients of 18 years and older caused by bacteria susceptible to moxifloxacin (see sections 4.4, 4.8 and 5.1). Moxifloxacin should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed:</p><p>- Acute bacterial sinusitis (adequately diagnosed)</p><p>- Acute exacerbations of chronic bronchitis (adequately diagnosed)</p><p>- Community acquired pneumonia, except severe cases</p><p>- Mild to moderate pelvic inflammatory disease (i.e. infections of female upper genital tract, including salpingitis and endometritis), without an associated tubo-ovarian or pelvic abscess.</p><p>Moxiflox 400 mg film-coated tablets are not recommended for use in monotherapy of mild to moderate pelvic inflammatory disease but should be given in combination with another appropriate antibacterial agent (e.g. a cephalosporin) due to increasing moxifloxacin resistance of <em>Neisseriagonorrhoeae</em> unless moxifloxacin-resistant <em>Neisseriagonorrhoeae</em> can be excluded (see sections 4.4 and 5.1).</p><p>Moxiflox 400 mg film-coated tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous moxifloxacin for the following indications:</p><p>- Community-acquired pneumonia</p><p>- Complicated skin and skin structure infections</p><p>Moxiflox 400 mg film-coated tablets should not be used to initiate therapy for any type of skin and skin structure infection or in severe community-acquired pneumonia.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:582px"><tbody><tr><td><p>&nbsp;</p></td><td><p><u>Posology (adults)</u></p><p>The recommended dose is one 400 mg film-coated tablet once daily.</p><p><em>Renal/hepatic impairment</em></p><p>No adjustment of dosage is required in patients with mild to severely impaired renal function or in patients on chronic dialysis i.e. haemodialysis and continuous ambulatory peritoneal dialysis (see section 5.2 for more details).</p><p>There is insufficient data in patients with impaired liver function (see section 4.3).</p><p><em>Other special populations</em></p><p>No adjustment of dosage is required in the elderly and in patients with low bodyweight.</p><p><em>Paediatric population</em></p><p>Moxifloxacin is contraindicated in children and adolescents (&lt; 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established (see section 4.3).</p><p><u>Method of administration</u></p><p>The film-coated tablet should be swallowed whole with sufficient liquid and may be taken independent of meals.</p><p><u>Duration of administration</u></p><p>Moxiflox 400 mg film-coated tablets should be used for the following treatment durations:</p><table border="0" cellspacing="0" cellpadding="0" style="width:549px"><tbody><tr><td style="vertical-align:top"><p>- Acute exacerbation of chronic bronchitis</p></td><td style="vertical-align:top"><p>5 - 10 days</p></td></tr><tr><td style="vertical-align:top"><p>- Community acquired pneumonia</p></td><td style="vertical-align:top"><p>10 days</p></td></tr><tr><td style="vertical-align:top"><p>- Acute bacterial sinusitis</p></td><td style="vertical-align:top"><p>7 days</p></td></tr><tr><td style="vertical-align:top"><p>- Mild to moderate pelvic inflammatory disease</p></td><td style="vertical-align:top"><p>14 days</p></td></tr></tbody></table><p>Moxiflox 400 mg film-coated tablets have been studied in clinical trials for up to 14 days treatment.</p><p><em>Sequential (intravenous followed by oral) therapy</em></p><p>In clinical studies with sequential therapy most patients switched from intravenous to oral therapy within 4 days (community-acquired pneumonia) or 6 days (complicated skin and skin structure infections). The recommended total duration of intravenous and oral treatment is 7 -14 days for community-acquired pneumonia and 7 -21 days for complicated skin and skin structure infections</p><p>The recommended dose (400 mg once daily) and duration of therapy for the indication being treated should not be exceeded.</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to moxifloxacin, other quinolones or to any of the excipients listed in section 6.1. 
- Pregnancy and lactation (see section 4.6). 
- Patients below 18 years of age. 
- Patients with a history of tendon disease/disorder related to quinolone treatment. 
Both in preclinical investigations and in humans, changes in cardiac electrophysiology have been observed following exposure to moxifloxacin, in the form of QT prolongation. For reasons of drug safety, moxifloxacin is therefore contraindicated in patients with: 
- Congenital or documented acquired QT prolongation 
- Electrolyte disturbances, particularly in uncorrected hypokalaemia
- Clinically relevant bradycardia
- Clinically relevant heart failure with reduced left-ventricular ejection fraction 
- Previous history of symptomatic arrhythmias 
Moxifloxacin should not be used concurrently with other drugs that prolong the QT interval (see also section 4.5). 
Due to limited clinical data, moxifloxacin is also contraindicated in patients with impaired liver function (Child Pugh C) and in patients with transaminases increase > 5fold ULN. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:582px"><tbody><tr><td><p>&nbsp;</p></td><td><p>Epidemiologic studies report an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population.</p><p>&nbsp;</p><p>Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or in patients diagnosed with pre-existing aortic aneurysm and/or aortic dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, Behcet`s disease, hypertension, known atherosclerosis).</p><p>&nbsp;</p><p>In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p><p>The benefit of moxifloxacin treatment especially in infections with a low degree of severity should be balanced with the information contained in the warnings and precautions section.</p><p><u>Prolongation of QTc interval and potentially QTc-prolongation-related clinical conditions</u></p><p>Moxifloxacin has been shown to prolong the QTc interval on the electrocardiogram in some patients. In the analysis of ECGs obtained in the clinical trial program, QTc prolongation with moxifloxacin was 6 msec &plusmn; 26 msec, 1.4% compared to baseline. As women tend to have a longer baseline QTc interval compared with men, they may be more sensitive to QTc-prolonging medications. Elderly patients may also be more susceptible to drug-associated effects on the QT interval.</p><p>Medication that can reduce potassium levels should be used with caution in patients receiving moxifloxacin (see also sections 4.3 and 4.5).</p><p>Moxifloxacin should be used with caution in patients with ongoing proarrhythmic conditions (especially women and elderly patients), such as acute myocardial ischaemia or QT prolongation as this may lead to an increased risk for ventricular arrhythmias (incl. torsade de pointes) and cardiac arrest (see also section 4.3). The magnitude of QT prolongation may increase with increasing concentrations of the drug. Therefore, the recommended dose should not be exceeded.</p><p>If signs of cardiac arrhythmia occur during treatment with moxifloxacin, treatment should be stopped and an ECG should be performed.</p><p><u>Hypersensitivity/allergic reactions</u></p><p>Hypersensitivity and allergic reactions have been reported for fluoroquinolones including moxifloxacin after first administration. Anaphylactic reactions can progress to a life-threatening shock, even after the first administration. In these cases moxifloxacin should be discontinued and suitable treatment (e.g. treatment for shock) initiated.</p><p><u>Severe liver disorders</u></p><p>Cases of fulminant hepatitis potentially leading to liver failure (including fatal cases) have been reported with moxifloxacin (see section 4.8). Patients should be advised to contact their doctor prior to continuing treatment if signs and symptoms of fulminant hepatic disease develop such as rapidly developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy.</p><p>Liver function tests/investigations should be performed in cases where indications of liver dysfunction occur.</p><p><u>Serious bullous skin reactions</u></p><p>Cases of bullous skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with moxifloxacin (see section 4.8). Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur.</p><p><u>Patients predisposed to seizures</u></p><p>Quinolones are known to trigger seizures. Use should be with caution in patients with CNS disorders or in the presence of other risk factors which may predispose to seizures or lower the seizure threshold. In case of seizures, treatment with moxifloxacin should be discontinued and appropriate measures instituted.</p><p><u>Peripheral neuropathy</u></p><p>Cases of sensory or sensorimotorpolyneuropathy resulting in paraesthesias, hypoaesthesias, dysaesthesias, or weakness have been reported in patients receiving quinolones including moxifloxacin. Patients under treatment with moxifloxacin should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop (see section 4.8).</p><p><u>Psychiatric reactions</u></p><p>Psychiatric reactions may occur even after the first administration of quinolones, including moxifloxacin. In very rare cases depression or psychotic reactions have progressed to suicidal thoughts and self-injurious behaviour such as suicide attempts (see section 4.8). In the event that the patient develops these reactions, moxifloxacin should be discontinued and appropriate measures instituted. Caution is recommended if moxifloxacin is to be used in psychotic patients or in patients with history of psychiatric disease.</p><p><u>Mental health</u></p><p>As with other quinolones, mental health changes have been reported such as disturbances in attention, disorientation, agitation, nervousness, memory impairment and delirium).</p><p><em><u>Hypoglycemia</u></em></p><p>As with other quinolones, hypoglycemia has been reported most often in diabetic patients, predominantly in the elderly population. In all diabetic patients, careful monitoring of blood glucose is recommended.</p><p><u>Antibiotic-associated diarrhoea incl. colitis</u></p><p>Antibiotic-associated diarrhoea (AAD) and antibiotic-associated colitis (AAC), including pseudomembranous colitis and <em>Clostridium difficile</em>-associated diarrhoea, has been reported in association with the use of broad spectrum antibiotics including moxifloxacin and may range in severity from mild diarrhoea to fatal colitis. Therefore it is important to consider this diagnosis in patients who develop serious diarrhoea during or after the use of moxifloxacin. If AAD or AAC is suspected or confirmed, ongoing treatment with antibacterial agents, including moxifloxacin, should be discontinued and adequate therapeutic measures should be initiated immediately. Furthermore, appropriate infection control measures should be undertaken to reduce the risk of transmission. Drugs inhibiting peristalsis are contraindicated in patients who develop serious diarrhoea.</p><p><u>Patients with myasthenia gravis</u></p><p>Moxifloxacin should be used with caution in patients with myasthenia gravis because the symptoms can be exacerbated.</p><p>Tendon inflammation and rupture (especially Achilles tendon), sometimes bilateral, may occur with quinolone therapy including moxifloxacin, even within 48 hours of starting treatment and have been reported up to several months after discontinuation of therapy. The risk of tendinitis and tendon rupture is increased in elderly patients and in those treated concurrently with corticosteroids. At the first sign of pain or inflammation, patients should discontinue treatment with moxifloxacin, rest the affected limb(s) and consult their doctor immediately in order to initiate appropriate treatment (e.g. immobilisation) for the affected tendon. (see sections 4.3 and 4.8).</p><p>Fluoroquinolones, including Moxiflox, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid Moxiflox in patients with known history of myasthenia gravis</p><p><u>Patients with renal impairment</u></p><p>Elderly patients with renal disorders should use moxifloxacin with caution if they are unable to maintain adequate fluid intake, because dehydration may increase the risk of renal failure.</p><p><u>Vision disorders</u></p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).</p><p><u>Prevention of photosensitivity reactions</u></p><p>Quinolones have been shown to cause photosensitivity reactions in patients. However, studies have shown that moxifloxacin has a lower risk to induce photosensitivity. Nevertheless patients should be advised to avoid exposure to either UV irradiation or extensive and/or strong sunlight during treatment with moxifloxacin.</p><p><u>Patients with glucose-6-phosphate dehydrogenase deficiency</u></p><p>Patients with a family history of, or actual glucose-6-phosphate dehydrogenase deficiency are prone to haemolytic reactions when treated with quinolones. Therefore, moxifloxacin should be used with caution in these patients.</p><p><u>Patients with galactose intolerance, Lapp lactase deficiency or glucose-galactosemalabsorption</u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactosemalabsorption should not take this medicine.</p><p><u>Patients with pelvic inflammatory disease</u></p><p>For patients with complicated pelvic inflammatory disease (e.g. associated with a tubo-ovarian or pelvic abscess), for whom an intravenous treatment is considered necessary, treatment with Moxiflox 400 mg film-coated tablets is not recommended.</p><p>Pelvic inflammatory disease may be caused by fluoroquinolone-resistant <em>Neisseriagonorrhoeae</em>. Therefore in such cases empirical moxifloxacin should be co-administered with another appropriate antibiotic (e.g. a cephalosporin) unless moxifloxacin-resistant <em>Neisseriagonorrhoeae</em> can be excluded. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.</p><p><u>Patients with special cSSSi</u></p><p>Clinical efficacy of intravenous moxifloxacin in the treatment of severe burn infections, fasciitis and diabetic foot infections with osteomyelitis has not been established.</p><p><u>Interference with biological tests</u></p><p>Moxifloxacin therapy may interfere with the <em>Mycobacterium</em> spp. culture test by suppression of mycobacterial growth causing false negative results in samples taken from patients currently receiving moxifloxacin.</p><p><u>Patients with MRSA infections</u></p><p>Moxifloxacin is not recommended for the treatment of MRSA infections. In case of a suspected or confirmed infection due to MRSA, treatment with an appropriate antibacterial agent should be started (see section 5.1).</p><p><u>Paediatric population</u></p><p>Due to adverse effects on the cartilage in juvenile animals (see section 5.3) the use of moxifloxacin in children and adolescents &lt; 18 years is contraindicated (see section 4.3).</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>Fluoroquinolones, including Moxiflox &reg;, are associated with an increased risk of&nbsp;tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of&nbsp;age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Interactions with medicinal products</u></p><p>An additive effect on QT interval prolongation of moxifloxacin and other medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an increased risk of ventricular arrhythmias, including torsade de pointes. Therefore, co-administration of moxifloxacin with any of the following medicinal products is contraindicated (see also section 4.3):</p><p>- anti-arrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide)</p><p>- anti-arrhythmics class III (e.g. amiodarone, sotalol, dofetilide, ibutilide)</p><p>- antipsychotics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)</p><p>- tricyclicantidepressive agents</p><p>- certain antimicrobial agents (saquinavir, sparfloxacin, erythromycin IV, pentamidine, antimalarials particularly halofantrine)</p><p>- certain antihistaminics (terfenadine, astemizole, mizolastine)</p><p>- others (cisapride, vincamine IV, bepridil, diphemanil).</p><p>Moxifloxacin should be used with caution in patients who are taking medication that can reduce potassium levels (e.g. loop and thiazide-type diuretics, laxatives and enemas [high doses], corticosteroids, amphotericin B) or medication that is associated with clinically significant bradycardia.</p><p>An interval of about 6 hours should be left between administration of agents containing bivalent or trivalent cations (e.g. antacids containing magnesium or aluminium, didanosine tablets, sucralfate and agents containing iron or zinc) and administration of moxifloxacin.</p><p>Concomitant administration of charcoal with an oral dose of 400 mg moxifloxacin led to a pronounced prevention of drug absorption and a reduced systemic availability of the drug by more than 80%. Therefore, the concomitant use of these two drugs is not recommended (except for overdose cases, see also section 4.9).</p><p>After repeated dosing in healthy volunteers, moxifloxacin increased C<sub>max</sub> of digoxinby approximately 30% without affecting AUC or trough levels. No precaution is required for use with digoxin.</p><p>In studies conducted in diabetic volunteers, concomitant administration of oral moxifloxacin with glibenclamide resulted in a decrease of approximately 21% in the peak plasma concentrations of glibenclamide. The combination of glibenclamide and moxifloxacin could theoretically result in a mild and transient hyperglycaemia. However, the observed pharmacokinetic changes for glibenclamide did not result in changes of the pharmacodynamic parameters (blood glucose, insulin). Therefore no clinically relevant interaction was observed between moxifloxacin and glibenclamide.</p><p><em>Changes in INR</em></p><p>A large number of cases showing an increase in oral anticoagulant activity have been reported in patients receiving antibacterial agents, especially fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and some cephalosporins. The infectious and inflammatory conditions, age and general status of the patient appear to be risk factors. Under these circumstances, it is difficult to evaluate whether the infection or the treatment caused the INR (international normalised ratio) disorder. A precautionary measure would be to more frequently monitor the INR. If necessary, the oral anticoagulant dosage should be adjusted as appropriate.</p><p>Clinical studies have shown no interactions following concomitant administration of moxifloxacin with: ranitidine, probenecid, oral contraceptives, calcium supplements, morphine administered parenterally, theophylline, cyclosporine or itraconazole.</p><p><em>In vitro </em>studies with human cytochrome P450 enzymes supported these findings. Considering these results a metabolic interaction via cytochrome P450 enzymes is unlikely.</p><p><u>Interaction with food</u></p><p>Moxifloxacin has no clinically relevant interaction with food including dairy products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:582px"><tbody><tr><td><p>&nbsp;</p></td><td><p><u>Pregnancy</u></p><p>pregnancy category C</p><p>The safety of moxifloxacin in human pregnancy has not been evaluated.. Animal studies have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals and reversible joint injuries described in children receiving some fluoroquinolones, moxifloxacin must not be used in pregnant women (see section 4.3).</p><p><u>Breastfeeding</u></p><p>There is no data available in lactating or nursing women. Preclinical data indicate that small amounts of moxifloxacin are secreted in milk. In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals, breast-feeding is contraindicated during moxifloxacin therapy (see section 4.3).</p><p><u>Fertility</u></p><p>Animal studies do not indicate impairment of fertility (see section 5.3).</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of moxifloxacin on the ability to drive and use machines have been performed. However, fluoroquinolones including moxifloxacin may result in an impairment of the patient&#39;s ability to drive or operate machinery due to CNS reactions (e.g. dizziness; acute, transient loss of vision, see section 4.8) or acute and short lasting loss of consciousness (syncope, see section 4.8). Patients should be advised to see how they react to moxifloxacin before driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:582px"><tbody><tr><td><p>&nbsp;</p></td><td><p>Adverse reactions based on all clinical trials with moxifloxacin 400 mg (oral and sequential therapy) sorted by frequencies are listed below:</p><p>Apart from nausea and diarrhoea all adverse reactions were observed at frequencies below 3%.</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as:</p><p>- common (&ge; 1/100 to &lt; 1/10)</p><p>- uncommon (&ge; 1/1,000 to &lt; 1/100)</p><p>- rare (&ge; 1/10,000 to &lt; 1/1,000)</p><p>- very rare (&lt; 1/10,000)</p><table border="1" cellspacing="0" cellpadding="0" style="width:566px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class (MedDRA)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>Superinfections due to resistant bacteria or fungi e.g. oral and vaginal candidiasis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia</p><p>Leucopenia(s)</p><p>Neutropenia</p><p>Thrombocytopenia</p><p>Thrombocythemia</p><p>Blood eosinophilia</p><p>Prothrombin time prolonged/INR increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Prothrombin level increased/INR decreased</p><p>Agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reaction (see section 4.4)</p></td><td style="vertical-align:top"><p>Anaphylaxis incl. very rarely life-threatening shock (see section 4.4)</p><p>Allergic oedema / angiooedema (incl. laryngeal oedema, potentially life-threatening, see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperlipidemia</p></td><td style="vertical-align:top"><p>Hyperglycemia</p><p>Hyperuricemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anxiety reactions</p><p>Psychomotor hyperactivity/ agitation</p></td><td style="vertical-align:top"><p>Emotional lability</p><p>Depression (in very rare cases potentially culminating in self-injurious behaviour, such as suicidal ideations/ thoughts, or suicide attempts, see section 4.4)</p><p>Hallucination</p></td><td style="vertical-align:top"><p>Depersonalization</p><p>Psychotic reactions (potentially culminating in self- injurious behaviour, such as suicidal ideations/ thoughts, or suicide attempts, see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Par- and Dysaesthesia</p><p>Taste disorders (incl. ageusia in very rare cases)</p><p>Confusion and disorientation</p><p>Sleep disorders (predominantly insomnia)</p><p>Tremor</p><p>Vertigo</p><p>Somnolence</p></td><td style="vertical-align:top"><p>Hypoaesthesia</p><p>Smell disorders (incl. anosmia)</p><p>Abnormal dreams</p><p>Disturbed coordination (incl. gait disturbances, esp. due to dizziness or vertigo)</p><p>Seizures incl. grand mal convulsions (see section 4.4)</p><p>Disturbed attention</p><p>Speech disorders</p><p>Amnesia</p><p>Peripheral neuropathy and polyneuropathy</p></td><td style="vertical-align:top"><p>Hyperaesthesia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual disturbances incl. diplopia and blurred vision (especially in the course of CNS reactions, see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Transient loss of vision (especially in the course of CNS reactions, see sections 4.4 and 4.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p><p>Hearing impairment incl. deafness (usually reversible)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>QT prolongation in patients with hypokalaemia (see sections 4.3 and 4.4)</p></td><td style="vertical-align:top"><p>QT prolongation (see section 4.4)</p><p>Palpitations</p><p>Tachycardia</p><p>Atrial fibrillation</p><p>Angina pectoris</p></td><td style="vertical-align:top"><p>Ventricular tachyarrhythmias</p><p>Syncope (i.e., acute and short lasting loss of consciousness)</p></td><td style="vertical-align:top"><p>Unspecified arrhythmias</p><p>Torsade de Pointes (see section 4.4)</p><p>Cardiac arrest (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasodilatation</p></td><td style="vertical-align:top"><p>Hypertension</p><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnea (including asthmatic conditions)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Nausea</p><p>Vomiting</p><p>Gastrointestinal and abdominal pains</p><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Decreased appetite and food intake</p><p>Constipation</p><p>Dyspepsia</p><p>Flatulence</p><p>Gastritis</p><p>Increased amylase</p></td><td style="vertical-align:top"><p>Dysphagia</p><p>Stomatitis</p><p>Antibiotic associated colitis (incl. pseudo-membranous colitis, in very rare cases associated with life-threatening complications, see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Increase in transaminases</p></td><td style="vertical-align:top"><p>Hepatic impairment (incl. LDH increase)</p><p>Increased bilirubin</p><p>Increased gamma-glutamyl-transferase</p><p>Increase in blood alkaline phosphatase</p></td><td style="vertical-align:top"><p>Jaundice</p><p>Hepatitis (predominantly cholestatic)</p></td><td style="vertical-align:top"><p>Fulminant hepatitis potentially leading to life-threatening liver failure (incl. fatal cases, see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritus</p><p>Rash</p><p>Urticaria</p><p>Dry skin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bullous skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis (potentially life-threatening, see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia</p><p>Myalgia</p></td><td style="vertical-align:top"><p>Tendonitis (see section 4.4)</p><p>Muscle cramp</p><p>Muscle twitching</p><p>Muscle weakness</p></td><td style="vertical-align:top"><p>Tendon rupture (see section 4.4)</p><p>Arthritis</p><p>Muscle rigidity</p><p>Exacerbation of symptoms of myasthenia gravis (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dehydration</p></td><td style="vertical-align:top"><p>Renal impairment (incl. increase in BUN and creatinine)</p><p>Renal failure (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Feeling unwell (predominantly asthenia or fatigue)</p><p>Painful conditions (incl. pain in back, chest, pelvic and extremities)</p><p>Sweating</p></td><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>There have been very rare cases of the following side effects reported following treatment with other fluoroquinolones, which might possibly also occur during treatment with moxifloxacin: hypernatraemia, hypercalcaemia, haemolyticanaemia, rhabdomyolysis, photosensitivity reactions (see section 4.4).</p><p>&nbsp;</p>&nbsp;<p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:549px"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p>&nbsp;The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2340-2356.</p><p>o Reporting hotline: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific countermeasures after accidental overdose are recommended. In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Concomitant administration of charcoal with a dose of 400 mg oral moxifloxacin will reduce systemic availability of the drug by more than 80%. The use of charcoal early during absorption may be useful to prevent excessive increase in the systemic exposure to moxifloxacin in cases of oral overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:582px"><tbody><tr><td><p>Pharmacotherapeutic group: Quinoloneantibacterials, fluoroquinolones, ATC code: J01MA14</p><p><u>Mechanism of action</u></p><p>Moxifloxacin has <em>in vitro</em> activity against a wide range of Gram-positive and Gram-negative pathogens.</p><p>The bactericidal action of moxifloxacin results from the inhibition of both type II topoisomerases (DNA gyrase and topoisomerase IV) required for bacterial DNA replication, transcription and repair. It appears that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety. The presence of the bulky bicycloamine substituent at the C-7 position prevents active efflux, associated with the <em>nor</em>A or <em>pmr</em>A genes seen in certain Gram-positive bacteria.</p><p>Pharmacodynamic investigations have demonstrated that moxifloxacin exhibits a concentration dependent killing rate. Minimum bactericidal concentrations (MBC) were found to be in the range of the minimum inhibitory concentrations (MIC).</p><p><u>Effect on the intestinal flora in humans</u></p><p>The following changes in the intestinal flora were seen in volunteers following oral administration of moxifloxacin: <em>Escherichia coli</em>, <em>Bacillus</em> spp., <em>Enterococcus</em> spp., and <em>Klebsiella</em> spp. were reduced, as were the anaerobes <em>Bacteroidesvulgatus</em>, <em>Bifidobacterium</em> spp., <em>Eubacterium</em> spp., and <em>Peptostreptococcus</em>spp.. For <em>Bacteroidesfragilis</em> there was an increase. These changes returned to normal within two weeks.</p><p><u>Mechanism of resistance</u></p><p>Resistance mechanisms that inactivate penicillins, cephalosporins, aminoglycosides, macrolides and tetracyclines do not interfere with the antibacterial activity of moxifloxacin. Other resistance mechanisms such as permeation barriers (common in <em>Pseudomonas aeruginosa</em>) and efflux mechanisms may also effect susceptibility to moxifloxacin.</p><p><em>In vitro</em> resistance to moxifloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Moxifloxacin is a poor substrate for active efflux mechanisms in Gram-positive organisms.</p><p>Cross-resistance is observed with other fluoroquinolones. However, as moxifloxacin inhibits both topoisomerase II and IV with similar activity in some Gram-positive bacteria, such bacteria may be resistant to other quinolones, but susceptible to moxifloxacin.</p><p><u>Breakpoints</u></p><p>EUCAST clinical MIC and disk diffusion breakpoints for moxifloxacin (01.01.2011):</p><table border="1" cellspacing="0" cellpadding="0" style="width:548px"><tbody><tr><td style="vertical-align:top"><p><strong>Organism</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus</em> spp.</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 24 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&lt; 21 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>S. pneumoniae</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 22 mm</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p><p>&ge; 22 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus</em> Groups A, B, C, G</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 18 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&lt; 15 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>H. influenzae</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 25 mm</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 25 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>M. catarrhalis</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 23 mm</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p><p>&lt; 23 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 20 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&lt; 17 mm</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints*</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>* Non-species related breakpoints have been determined mainly on the basis of pharmacokinetic/pharmacodynamic data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and are not for use with species where interpretative criteria remain to be determined.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><u>Microbiological Susceptibility</u></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information of resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought where the local prevalence of resistance is such that utility of the agent in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0" style="width:548px"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Gardnerellavaginalis</em></p><p><em>Staphylococcus aureus</em>* (methicillin-susceptible)</p><p><em>Streptococcus agalactiae</em> (Group B)</p><p><em>Streptococcus milleri</em> group* (<em>S. anginosus, S. constellatus and S. intermedius</em>)</p><p><em>Streptococcus pneumoniae</em>*</p><p><em>Streptococcus pyogenes</em>* (Group A)</p><p><em>Streptococcus viridans</em>group<em> (S. viridans, S. mutans, S. mitis, S. sanguinis, S. salivarius, S. thermophilus)</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Acinetobacterbaumanii</em></p><p><em>Haemophilusinfluenzae</em>*</p><p><em>Haemophilusparainfluenzae</em>*</p><p><em>Legionellapneumophila</em></p><p><em>Moraxella (Branhamella) catarrhalis</em>*</p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Fusobacterium</em> spp.</p><p><em>Prevotella</em> spp.</p></td></tr><tr><td style="vertical-align:top"><p><u>&ldquo;Other&rdquo; micro-organisms</u></p><p><em>Chlamydophila (Chlamydia) pneumoniae</em>*</p><p><em>Chlamydia trachomatis*</em></p><p><em>Coxiellaburnetii</em></p><p><em>Mycoplasmagenitalium</em></p><p><em>Mycoplasmahominis</em></p><p><em>Mycoplasmapneumoniae</em>*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcusfaecalis*</em></p><p><em>Enterococcusfaecium* </em></p><p><em>Staphylococcus aureus</em> (methicillin-resistant)<sup>+</sup></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Enterobacter cloacae</em>*</p><p><em>Escherichia coli</em>*</p><p><em>Klebsiellapneumoniae</em>*<sup>#</sup></p><p><em>Klebsiellaoxytoca</em></p><p><em>Neisseriagonorrhoeae*</em><sup>+</sup></p><p><em>Proteus mirabilis</em>*</p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Bacteroidesfragilis*</em></p><p><em>Peptostreptococcus</em> spp.*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Pseudomonas aeruginosa</em></p></td></tr><tr><td style="vertical-align:top"><p>*Activity has been satisfactorily demonstrated in susceptible strains in clinical studies in the approved clinical indications.</p><p><sup>#</sup>ESBL-producing strains are commonly resistant to fluoroquinolones</p><p><sup>+</sup>Resistance rate &gt; 50% in one or more countries</p></td></tr></tbody></table><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:582px"><tbody><tr><td><p>&nbsp;</p></td><td><p><u>Absorption and Bioavailability</u></p><p>Following oral administration moxifloxacin is rapidly and almost completely absorbed. The absolute bioavailability amounts to approximately 91%.</p><p>Pharmacokinetics are linear in the range of 50 - 800 mg single dose and up to 600 mg once daily dosing over 10 days. Following a 400 mg oral dose peak concentrations of 3.1 mg/l are reached within 0.5 - 4 h post administration. Peak and trough plasma concentrations at steady-state (400 mg once daily) were 3.2 and 0.6 mg/l, respectively. At steady-state the exposure within the dosing interval is approximately 30% higher than after the first dose.</p><p><u>Distribution</u></p><p>Moxifloxacin is distributed to extravascular spaces rapidly; after a dose of 400 mg an AUC of 35 m∙gh/l is observed. The steady-state volume of distribution (Vss) is approximately 2 l/kg. <em>In vitro </em>and <em>ex vivo</em> experiments showed a protein binding of approximately 40 - 42% independent of the concentration of the drug. Moxifloxacin is mainly bound to serum albumin.</p><p>The following peak concentrations (geometric mean) were observed following administration of a single oral dose of 400 mg moxifloxacin:</p><table border="1" cellspacing="0" cellpadding="0" style="width:548px"><tbody><tr><td style="vertical-align:top"><p><strong>Tissue</strong></p></td><td style="vertical-align:top"><p><strong>Concentration</strong></p></td><td style="vertical-align:top"><p><strong>Site: Plasma ratio</strong></p></td></tr><tr><td style="vertical-align:top"><p>Plasma</p></td><td style="vertical-align:top"><p>3.1 mg/l</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Saliva</p></td><td style="vertical-align:top"><p>3.6 mg/l</p></td><td style="vertical-align:top"><p>0.75 - 1.3</p></td></tr><tr><td style="vertical-align:top"><p>Blister fluid</p></td><td style="vertical-align:top"><p>1.6<sup>1</sup> mg/l</p></td><td style="vertical-align:top"><p>1.7<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Bronchial mucosa</p></td><td style="vertical-align:top"><p>5.4 mg/kg</p></td><td style="vertical-align:top"><p>1.7 - 2.1</p></td></tr><tr><td style="vertical-align:top"><p>Alveolar macrophages</p></td><td style="vertical-align:top"><p>56.7 mg/kg</p></td><td style="vertical-align:top"><p>18.6 - 70.0</p></td></tr><tr><td style="vertical-align:top"><p>Epithelial lining fluid</p></td><td style="vertical-align:top"><p>20.7 mg/l</p></td><td style="vertical-align:top"><p>5 - 7</p></td></tr><tr><td style="vertical-align:top"><p>Maxillary sinus</p></td><td style="vertical-align:top"><p>7.5 mg/kg</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Ethmoid sinus</p></td><td style="vertical-align:top"><p>8.2 mg/kg</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Nasal polyps</p></td><td style="vertical-align:top"><p>9.1 mg/kg</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial fluid</p></td><td style="vertical-align:top"><p>1.0<sup>2</sup> mg/l</p></td><td style="vertical-align:top"><p>0.8 - 1.4<sup>2,3</sup></p></td></tr><tr><td style="vertical-align:top"><p>Female genital tract*</p></td><td style="vertical-align:top"><p>10.2<sup>4</sup> mg/kg</p></td><td style="vertical-align:top"><p>1.72<sup>4</sup></p></td></tr></tbody></table><p>* intravenous administration of a single 400 mg dose</p><p><sup>1</sup> 10 h after administration</p><p><sup>2</sup> unbound concentration</p><p><sup>3</sup> from 3 h up to 36 h post dose</p><p><sup>4</sup> at the end of infusion</p><p><u>Biotransformation</u></p><p>Moxifloxacin undergoes Phase II biotransformation and is excreted via renal and biliary/faecal pathways as unchanged drug as well as in the form of a sulpho-compound (M1) and a glucuronide (M2). M1 and M2 are the only metabolites relevant in humans, both are microbiologically inactive.</p><p>In clinical Phase I and <em>in vitro</em> studies no metabolic pharmacokinetic interactions with other drugs undergoing Phase I biotransformation involving cytochrome P450 enzymes were observed. There is no indication of oxidative metabolism.</p><p><u>Elimination</u></p><p>Moxifloxacin is eliminated from plasma with a mean terminal half life of approximately 12 hours. The mean apparent total body clearance following a 400 mg dose ranges from 179 to 246 ml/min. Renal clearance amounted to about 24 - 53 ml/min suggesting partial tubular reabsorption of the drug from the kidneys.</p><p>After a 400 mg dose, recovery from urine (approximately 19% for unchanged drug, approximately 2.5% for M1, and approximately 14% for M2) and faeces (approximately 25% of unchanged drug, approximately 36% for M1, and no recovery for M2) totalled to approximately 96%.</p><p>Concomitant administration of moxifloxacin with ranitidine or probenecid did not alter renal clearance of the parent drug.</p><p><em>Elderly and patients with low body weight</em></p><p>Higher plasma concentrations are observed in healthy volunteers with low body weight (such as women) and in elderly volunteers.</p><p><em>Renal impairment</em></p><p>The pharmacokinetic properties of moxifloxacin are not significantly different in patients with renal impairment (including creatinine clearance &gt; 20 ml/min/1.73 m<sup>2</sup>). As renal function decreases, concentrations of the M2 metabolite (glucuronide) increase by up to a factor of 2.5 (with a creatinine clearance of &lt; 30 ml/min/1.73 m<sup>2</sup>).</p><p><em>Hepatic impairment</em></p><p>On the basis of the pharmacokinetic studies carried out so far in patients with liver failure (Child Pugh A, B), it is not possible to determine whether there are any differences compared with healthy volunteers. Impaired liver function was associated with higher exposure to M1 in plasma, whereas exposure to parent drug was comparable to exposure in healthy volunteers. There is insufficient experience in the clinical use of moxifloxacin in patients with impaired liver function.</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects on the haematopoetic system (slight decreases in the number of erythrocytes and platelets) were seen in rats and monkeys. As with other quinolones, hepatotoxicity (elevated liver enzymes and vacuolar degeneration) was seen in rats, monkeys and dogs. In monkeys CNS toxicity (convulsions) occurred. These effects were seen only after treatment with high doses of moxifloxacin or after prolonged treatment.</p><p>Moxifloxacin, like other quinolones, was genotoxic in <em>in vitro</em> tests using bacteria or mammalian cells. Since these effects can be explained by an interaction with the gyrase in bacteria and - at higher concentrations - by an interaction with the topoisomerase II in mammalian cells, a threshold concentration for genotoxicity can be assumed. In <em>in vivo</em>tests, no evidence of genotoxicity was found despite the fact that very high moxifloxacin doses were used. Thus, a sufficient margin of safety to the therapeutic dose in man can be provided. Moxifloxacin was non-carcinogenic in an initiation-promotion study in rats.</p><p>Many quinolones are photoreactive and can induce phototoxic, photomutagenic and photocarcinogenic effects. In contrast, moxifloxacin was proven to be devoid of phototoxic and photogenotoxic properties when tested in a comprehensive programmeof<em>in vitro </em>and <em>in vivo</em> studies. Under the same conditions other quinolones induced effects.</p><p>At high concentrations, moxifloxacin is an inhibitor of the rapid component of the delayed rectifier potassium current of the heart and may thus cause prolongations of the QT interval. Toxicological studies performed in dogs using oral doses of &ge; 90 mg/kg leading to plasma concentrations &ge; 16 mg/l caused QT prolongations, but no arrhythmias. Only after very high cumulative intravenous administration of more than 50fold the human dose (&gt; 300 mg/kg), leading to plasma concentrations of &ge; 200 mg/l (more than 40fold the therapeutic level), reversible, non-fatal ventricular arrhythmias were seen.</p><p>Quinolones are known to cause lesions in the cartilage of the major diarthrodial joints in immature animals. The lowest oral dose of moxifloxacin causing joint toxicity in juvenile dogs was four times the maximum recommended therapeutic dose of 400 mg (assuming a 50 kg bodyweight) on a mg/kg basis, with plasma concentrations two to three times higher than those at the maximum therapeutic dose.</p><p>Toxicity tests in rats and monkeys (repeated dosing up to six months) revealed no indication regarding an oculotoxic risk. In dogs, high oral doses (&ge; 60 mg/kg) leading to plasma concentrations &ge; 20 mg/l caused changes in the electroretinogram and in isolated cases an atrophy of the retina.</p><p>Reproductive studies performed in rats, rabbits and monkeys indicate that placental transfer of moxifloxacin occurs. Studies in rats (p.o. and i.v.) and monkeys (p.o.) did not show evidence of teratogenicity or impairment of fertility following administration of moxifloxacin. A slightly increased incidence of vertebral and rib malformations was observed in foetuses of rabbits but only at a dose (20 mg/kg i.v.) which was associated with severe maternal toxicity. There was an increase in the incidence of abortions in monkeys and rabbits at human therapeutic plasma concentrations. In rats, decreased foetal weights, an increased prenatal loss, a slightly increased duration of pregnancy and an increased spontaneous activity of some male and female offspring was observed at doses which were 63 times the maximum recommended dose on a mg/kg basis with plasma concentrations in the range of the human therapeutic dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Tablet Core</u></strong><u>:</u>&nbsp;</p><p>Lactose&nbsp;Anhydrous&nbsp;NF D.C.</p><p>Povidone&nbsp;PVP K30</p><p>Croscarmellose&nbsp;Sodium Type&nbsp;A</p><p>Colloidal&nbsp;Silicon&nbsp;Dioxide</p><p>Magnesium&nbsp;Stearate</p><p>&nbsp;</p><p><strong><u>Film-Coat</u></strong></p><p>Hydroxypropyl Methylcellulose 5cps</p><p>Titanium Dioxide Pharma Grade</p><p>Purified Talc</p><p>Polyethylene Glycol MW 6000</p><p>Iron Oxide Red</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:582px"><tbody><tr><td><p>Not applicable.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:582px"><tbody><tr><td><p>Store below 30&deg;C</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cartons containing Aluminum thin strip soft tamper plain, dull side lacquer laminated to polyamide film. Bright side lacquer laminated to PVC with hard tempered aluminium.</p><p>The film-coated tablets are available in packs of&nbsp;&nbsp; 5 and 7 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:582px"><tbody><tr><td><p>No special requirements.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dammam Pharma
Saudi Arabia
Address: 1st industrial city, unit No.1, PO.BOX: 7137, Dammam 32234-4384
Phone: +966138216444
Fax: +966138216422
Email: regulatory-affairs@dammampharma.sa

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>